Robert E. Landry - Jan 4, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Jan 4, 2024
Transactions value $
-$124,141
Form type
4
Date filed
1/8/2024, 04:02 PM
Previous filing
Jan 4, 2024
Next filing
Jan 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $189K +500 +2.23% $378.98 22.9K Jan 4, 2024 Direct
transaction REGN Common Stock Tax liability -$314K -342 -1.49% $917.05 22.6K Jan 4, 2024 Direct
holding REGN Common Stock 270 Jan 4, 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -500 -3.13% $0.00 15.5K Jan 4, 2024 Common Stock 500 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.